Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of Hereditary Transthyretin-Mediated (ATTRv) Amyloidosis With a V122I or T60A Mutation

NCT04201418 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.

NCT NCT04201418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04201418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of Hereditary Transthyretin-Mediated (ATTRv) Amyloidosis With a V122I or T60A Mutation
Lead sponsor
Alnylam Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
December 18, 2019
Completion date
May 24, 2022
Enrollment
67 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary transthyretin-mediated (attrv) amyloidosis, polyneuropathy